Mel-CAM Antibody (C-11): sc-374414

Mel-CAM Antibody (C-11) is a mouse monoclonal IgA antibody that detects Mel-CAM in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Mel-CAM, also known as MCAM, MUC18, or CD146, is a transmembrane glycoprotein encoded by the human Mel-CAM gene, which plays a crucial role in cell adhesion and is a member of the immunoglobulin superfamily. This protein consists of 603 amino acids, featuring a signal peptide, five immunoglobulin-like domains, a transmembrane region, and a short cytoplasmic tail. Mel-CAM is predominantly expressed in advanced primary and metastatic melanomas, as well as in neuroectodermal lineage cell lines, but is absent in normal melanocytes. Notably, Mel-CAM is present in approximately 80% of advanced primary human melanomas and is closely associated with the progression of metastatic disease. The activation of Mel-CAM triggers an outside-in signaling pathway involving protein tyrosine kinases such as Fyn, focal adhesion kinase (FAK), and paxillin, which are essential for regulating the dynamics of actin cytoskeleton rearrangement. This function is vital for maintaining thymic architecture and overall immune system functionality, highlighting the importance of Mel-CAM in both tumor biology and immune response.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Mel-CAM Antibody (C-11) References:

1. Melanoma cell adhesion molecule (MCAM/CD146) is expressed on human luteinizing granulosa cells: enhancement of its expression by hCG, interleukin-1 and tumour necrosis factor-alpha.  |  Yoshioka, S., et al. 2003. Mol Hum Reprod. 9: 311-9. PMID: 12771231
2. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization.  |  Hafner, C., et al. 2005. J Invest Dermatol. 124: 125-31. PMID: 15654965
3. A dileucine motif targets MCAM-l cell adhesion molecule to the basolateral membrane in MDCK cells.  |  Guezguez, B., et al. 2006. FEBS Lett. 580: 3649-56. PMID: 16756976
4. Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.  |  Rapanotti, MC., et al. 2014. Arch Dermatol Res. 306: 527-37. PMID: 24902661
5. β-1,3-Galactosyl-O-Glycosyl-Glycoprotein β-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.  |  Sumardika, IW., et al. 2018. Oncol Res. 26: 431-444. PMID: 28923134
6. MCAM abnormal expression and clinical outcome associations are highly cancer dependent as revealed through pan-cancer analysis.  |  An, Y., et al. 2020. Brief Bioinform. 21: 709-718. PMID: 30815677
7. Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma.  |  Zhang, H., et al. 2022. iScience. 25: 104918. PMID: 36093059
8. CD146/MCAM links doxorubicin-induced epigenetic dysregulation to the impaired fatty acid transportation in H9c2 cardiomyoblasts.  |  Hasan, AU., et al. 2024. Biochem Biophys Res Commun. 693: 149370. PMID: 38100998
9. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes.  |  Pickl, WF., et al. 1997. J Immunol. 158: 2107-15. PMID: 9036955
10. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion.  |  Shih, IM., et al. 1997. Cancer Res. 57: 3835-40. PMID: 9288796

The preferred Mel-CAM antibody is Mel-CAM Antibody (P1H12): sc-18837.